Plasmacytoma
Symptoms, Doctors, Treatments, Advances & More

Plasmacytoma Overview

Save information for later
Sign Up

Learn About Plasmacytoma

Who are the top Plasmacytoma Local Doctors?
Elite in Plasmacytoma
Dr. Paul G. Richardson
Hematology Oncology | Oncology | Hematology
Elite in Plasmacytoma
Dr. Paul G. Richardson
Hematology Oncology | Oncology | Hematology

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center

450 Brookline Avenue, 
Boston, MA 
617-632-2104
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Richardson is a Hematologist Oncology specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Richardson is rated as an Elite provider by MediFind in the treatment of Plasmacytoma. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft. Dr. Richardson is board certified in Medical Oncology.

Elite in Plasmacytoma
Youlia M. Kirova
Elite in Plasmacytoma
Youlia M. Kirova
Paris, FR 

Youlia Kirova practices practicing medicine in Paris, France. Kirova is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. They are also highly rated in 14 other conditions, according to our data. Their clinical expertise encompasses Breast Cancer, Plasmacytoma, Mediastinal Tumor, Mastectomy, and Bone Marrow Aspiration.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Plasmacytoma
Philippe A. Moreau
Elite in Plasmacytoma
Philippe A. Moreau
Head And Neck, 
Nantes, FR 

Philippe Moreau practices practicing medicine in Nantes, France. Mr. Moreau is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Plasmacytoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

View All Doctors
What are the latest Plasmacytoma Clinical Trials?
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Who is this study for: Patients with relapsed/refractory hematological malignances
Enrollment Status: Recruiting
Publish Date: March 18, 2026
Intervention Type: Drug
Study Drugs: Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
Study Phase: Phase 1/Phase 2

Summary: The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I Clinical Study to Evaluate the Safety and Pharmacokinetics of TQB2934 Subcutaneous Preparation for Injection in Subjects With Malignant Plasma Cell Tumors
A Phase I Clinical Study to Evaluate the Safety and Pharmacokinetics of TQB2934 Subcutaneous Preparation for Injection in Subjects With Malignant Plasma Cell Tumors
Enrollment Status: Recruiting
Publish Date: December 11, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody，and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T ce...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center